Sarepta Therapeutics Inc. and FDA appeared at odds over whether a placebo-controlled trial should have, or could have, been conducted as part of the later development stages of Exondys 51 in Duchenne muscular dystrophy.
A Sarepta official said recently that the company, patients and physicians concluded that a Phase III placebo-controlled trial would not...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?